Nissay Asset Management Corp Japan ADV reduced its position in ABIOMED, Inc. (NASDAQ:ABMD) by 1.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 4,398 shares of the medical equipment provider’s stock after selling 56 shares during the period. Nissay Asset Management Corp Japan ADV’s holdings in ABIOMED were worth $1,062,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Toth Financial Advisory Corp purchased a new stake in shares of ABIOMED in the 2nd quarter valued at about $43,000. Synovus Financial Corp lifted its holdings in shares of ABIOMED by 60.6% in the 1st quarter. Synovus Financial Corp now owns 212 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 80 shares during the last quarter. Sugarloaf Wealth Management LLC lifted its holdings in shares of ABIOMED by 100.0% in the 1st quarter. Sugarloaf Wealth Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 125 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of ABIOMED by 107.1% in the 4th quarter. Quadrant Capital Group LLC now owns 261 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 135 shares during the last quarter. Finally, Bainco International Investors purchased a new stake in shares of ABIOMED in the 1st quarter valued at about $39,000. 94.43% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ ABMD opened at $299.94 on Friday. The stock has a fifty day moving average price of $265.61 and a 200 day moving average price of $198.10. The company has a market cap of $13.51 billion, a P/E ratio of 67.86, a P/E/G ratio of 4.79 and a beta of 0.94. ABIOMED, Inc. has a 12-month low of $119.01 and a 12-month high of $302.97.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, April 30th. The medical equipment provider reported $0.70 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.26). The business had revenue of $206.66 million for the quarter, compared to analyst estimates of $209.58 million. ABIOMED had a net margin of 24.14% and a return on equity of 18.51%. The firm’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.60 earnings per share. As a group, equities analysts predict that ABIOMED, Inc. will post 3.21 earnings per share for the current fiscal year.
In other news, Director Dorothy E. Puhy sold 7,500 shares of the stock in a transaction dated Wednesday, July 15th. The shares were sold at an average price of $275.00, for a total transaction of $2,062,500.00. Following the transaction, the director now owns 7,652 shares of the company’s stock, valued at $2,104,300. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.40% of the company’s stock.
Several equities analysts recently issued reports on the company. Morgan Stanley boosted their price target on ABIOMED from $149.00 to $152.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. SVB Leerink boosted their price target on ABIOMED from $195.00 to $225.00 and gave the company a “market perform” rating in a research report on Thursday, May 28th. OTR Global upgraded ABIOMED to a “positive” rating in a research report on Monday, July 13th. Zacks Investment Research cut ABIOMED from a “hold” rating to a “sell” rating and set a $160.00 price target on the stock. in a research report on Wednesday, April 8th. Finally, BTIG Research cut ABIOMED to a “hold” rating in a research report on Wednesday, May 27th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $186.40.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Article: Liquidity
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.